AGA Backs Fecal Microbiota-Based Therapies for Recurrent C. Diff
The American Gastroenterological Association (AGA) endorsed the use of fecal microbiota-based therapies for recurrent Clostridioides difficile infections (CDIs) in new guideline recommendations, but advised against such therapies for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The guideline panel first noted that immunocompetent adults with recurrent CDIs should receive fecal microbiota-based therapies upon completion […]
Fecal Matter Transplant Shows Promise in Cirrhosis
VIENNA — Fecal microbiota transplants (FMT) helped reset gut microbiota, leading to strengthened gut barrier function and mucosal immunity in patients with cirrhosis, according to a U.K. trial. For this pilot study called PROFIT, 50 grams of liquid frozen fecal microbiota was transplanted into the jejunum via endoscopy in 22 patients while another 10 patients […]
FDA Advisors Back Fecal Microbiome Treatment for Recurrent C. Diff
An FDA advisory board recommended the agency approve a fecal microbiota transfer (FMT) product for recurrent Clostridium difficile infections. By a vote of 13-4 on Thursday, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), said RBX2660 was effective for treating patients with recurrent C. diff infections who failed first-line antimicrobial therapy. Safety landed in […]
Did Fecal Transplant Stop COVID in Its Tracks?
Fecal microbiota transplant (FMT) was safe in two hospitalized patients who were co-infected with cases of COVID-19 that quickly resolved, raising questions about the procedure’s effect on the virus. FMT was effective for the two patients, who were receiving the treatment for Clostridium difficile (C. difficile) infections and subsequently tested positive for COVID-19, reported Jaroslaw […]